Home › Companies › VTVT

vTv Therapeutics

Market cap $69.4M 4.0M shares (vendor count, Nov 18, 2026) × $17.29 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. CATT1 Ph3 toplinemid-2027CATT1 Ph3 topline, mid-2027, major
  2. Cadisegliatin T2D Ph2 start2H 2027Cadisegliatin T2D Ph2 start, 2H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Discontinued (1)

Capital (as filed)

Cash
$77.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$10.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$77.2M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on vTv Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative vTv Therapeutics (VTVT): Scientific Deep Dive for Cadisegliatin and Pipeline Products Hepatoselective chemistry addresses historical GKA toxicity, Phase 2 hypoglycemia benefit is the real value driver, and the company is fully funded to the binary Phase 3 readout in 2H 2026.
  2. Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) – A Biotech Delay Hits Phase 3 Trial timeline slipped to 2027 but thesis is delayed not broken; balance sheet covers the extended runway and the hepatoselective chemistry conviction is unchanged.
  3. Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - Smart Money Buys the Delay Millennium Management's 5% passive stake validates the runway math and confirms institutional confidence in the science despite the enrollment delay.
  4. Hold UPDATE: vTv Therapeutics (VTVT) – The ATM Refresh on Earnings Day ATM refresh signals potential dilution overhang and burn rate came in higher than modeled, making new entry unattractive until the ATM overhang clears or a tangible enrollment update arrives.
  5. Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - The Gun They Didn't Fire Zero ATM shares sold in two consecutive quarters and enrollment on track for Q3 2026 removes the specific dilution overhang that triggered the May downgrade, restoring the speculative buy stance.
  6. Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - The Clock Is Set CATT1 fully enrolled at 166 patients with topline now pinned to mid-2027; enrollment risk is retired and the binary readout remains the sole remaining catalyst.
  7. Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - Millennium Doubles Down Millennium grew its stake ~73% to 8.7% during the dead-money drift and before enrollment news, reinforcing institutional conviction in the mid-2027 binary event.
  8. Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - Homework Done, Stock Down 28% ATM unused for a third straight quarter, burn slowed to ~$10M, runway language upgraded back to 'well through' topline, and Hybrid CATT1 started — operational checklist is cleaner despite the 28% price drop.
  9. Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - A Seller Who Had No Choice Samsara's block sale was a forced LP-redemption event, not a discretionary exit; the fund retained ~98% of its economic position and the clinical story is unchanged.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)